The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.

598890 Disclosed herein are compounds of formula (I) U1-M-U2 wherein the variables are defined in the specification the use of said compounds in the treatment of cancer specifically by sensitising a cell to an apoptotic signal. Additionally said compounds may be used for sequential or concomitant use with a pharmaceutical compound which induces an apoptotic signal such as cytarabine fludarabine 5-fluoro-2'-deoxyuridine 5 gemcitabine methotrexate bleomycin cisplatin cyclophosphamide adriamycin (d...

The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, and fludarabine for the treatment of cell proliferative disorders, such as undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL)

The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing 4-(3-(2H-123-triazol-2-yl)phenylamino)-2-(1R2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof and fludarabine for the treatment of cell proliferative disorders such as undesired acute myeloid leukemia (AML) chronic lymphocytic leukemia (CLL) non-Hodgkin lymphoma (NHL) including diffuse large B cell lymphoma (DLBCL); mantle cell lym...

The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof and fludarabine for the treatment of cell proliferative disorders such as undesired acute myeloid leukemia (AML) chronic lymphocytic leukemia (CLL) non-Hodgkin lymphoma (NHL) including diffuse large B cell lymphoma (DLBCL); mantle cell lym...

The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, and fludarabine for the treatment of cell proliferative disorders, such as undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL)

The present invention describes CD37 antibodies, especially A2 and B2, for the treatment of patients with CLL, especially of patients belonging to a "high risk" or "ultra-high risk" group of patients. Those patients are either patients who are refractory to fludarabine treatment or patients who carry a genetic marker which is indicative for poor prognosis or increased risk of treatment failure, e.g. patients with TP53 dysfunction or deletion of chromosome 17p13, or patients after failure to prev...